Ueno S, Susa N, Furukawa Y, Sugiyama M
Department of Veterinary Public Health, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Japan.
Toxicol Appl Pharmacol. 1995 Dec;135(2):165-71. doi: 10.1006/taap.1995.1219.
The formation of paramagnetic chromium in the liver of male mice dosed with K2Cr2O7 (10, 20, and 40 mg Cr/kg) by a single ip injection was investigated by electron spin resonance (ESR) spectrometry. Both Cr(V) and Cr(III) complexes were detected in the mice livers at 15 min to 12 hr after Cr(VI) injection. The time course (15 min-12 hr) for the formation of paramagnetic Cr revealed that the hepatic levels of Cr(V) complexes decreased quickly during the first hour but decreased more slowly over the next 11 hr. However, in contrast to Cr(V), Cr(III) complexes appeared to persist for 12 hr after Cr(VI) treatment based on figures of Cr(III) signal. Thus, Cr(III) may be the ultimate form following reduction of Cr(VI) in liver. The total Cr content in liver of mice dosed with dichromate was also increased in a dose-dependent fashion (10-40 mg Cr/kg). However, Cr content in liver remained at similar levels for 15 min-6 hr, and slightly decreased at 12 hr after Cr(VI) injection. Under the same experimental conditions, hepatotoxicity, as estimated by the increase of serum ornithine carbamyl transferase activity, appeared at 3 hr after 20 and 40 mg Cr/kg of Cr(VI) injection, while 10 mg Cr/kg of Cr(VI) produced no hepatotoxicity even at 12 hr. Predosing with phenobarbital, which increased the hepatic levels of cytochrome P450, resulted in a decrease of the levels of Cr(V) and in a small increase of Cr content, without affecting Cr(VI) hepatotoxicity. On the other hand, pretreatment with buthionine sulfoximine, which depleted hepatic glutathione (GSH) levels, caused a decrease of Cr(VI) hepatotoxicity, but the levels of Cr(V) and Cr in the liver remained unchanged. These results demonstrated that in vivo formation of paramagnetic Cr, in particular Cr(V), in liver of mice is clearly detected and quantified by ESR spectrometry and that hepatic levels of cytochrome P450 and GSH are associated with the induction of biological effects by Cr(VI) in liver in vivo. The results also suggested that the formation of Cr(V) was not the only mechanism involved in the induction of hepatotoxicity by Cr(VI) compounds.
通过电子自旋共振(ESR)光谱法研究了单次腹腔注射重铬酸钾(10、20和40mg Cr/kg)的雄性小鼠肝脏中顺磁性铬的形成。在注射六价铬后15分钟至12小时内在小鼠肝脏中检测到了五价铬和三价铬配合物。顺磁性铬形成的时间进程(15分钟至12小时)表明,五价铬配合物的肝脏水平在最初1小时内迅速下降,但在接下来的11小时内下降得更慢。然而,与五价铬相反,基于三价铬信号的数据,三价铬配合物在六价铬处理后似乎持续存在12小时。因此,三价铬可能是肝脏中六价铬还原后的最终形式。用重铬酸盐给药的小鼠肝脏中的总铬含量也呈剂量依赖性增加(10 - 40mg Cr/kg)。然而,肝脏中的铬含量在15分钟至6小时内保持在相似水平,并在注射六价铬后12小时略有下降。在相同的实验条件下,通过血清鸟氨酸氨基甲酰转移酶活性的增加来估计的肝毒性在注射20和40mg Cr/kg六价铬后3小时出现,而10mg Cr/kg六价铬即使在12小时也未产生肝毒性。预先给予苯巴比妥可增加细胞色素P450的肝脏水平,导致五价铬水平降低和铬含量略有增加,而不影响六价铬的肝毒性。另一方面,用丁硫氨酸亚砜胺预处理可耗尽肝脏谷胱甘肽(GSH)水平,导致六价铬肝毒性降低,但肝脏中五价铬和铬的水平保持不变。这些结果表明,通过ESR光谱法可以清楚地检测和定量小鼠肝脏中顺磁性铬,特别是五价铬的体内形成,并且细胞色素P450和GSH的肝脏水平与六价铬在体内肝脏中诱导的生物学效应相关。结果还表明,五价铬的形成不是六价铬化合物诱导肝毒性的唯一机制。